Boehringer Ingelheim Introduces Vetmedin Solution (Pimobendan Oral Solution), for Congestive Heart Failure in Dogs
Shots:
- Boehringer Ingelheim has introduced Vetmedin flavorless, twice-daily, oral solution for managing canine congestive heart failure from MMVD or DCM
- Vetmedin’s studies have demonstrated increased survival time and quality of life in dogs due to MMVD or DCM
- Vetmedin was previously approved as chewable tablets for use with concurrent therapy in managing congestive heart failure (e.g., furosemide, etc.) as needed. In addition, BI’s portfolio consists of Vetmedin-CA1 (conditionally approved by the US FDA) to delay heart failure symptoms in dogs with stage B2 preclinical MMVD
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim Join Forces with Circle Pharma to Develop a Novel Precision Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
